MediciNova (NASDAQ: MNOV) is one of 480 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare MediciNova to similar companies based on the strength of its valuation, earnings, risk, dividends, analyst recommendations, institutional ownership and profitability.
Institutional & Insider Ownership
18.8% of MediciNova shares are owned by institutional investors. Comparatively, 47.7% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 15.2% of MediciNova shares are owned by insiders. Comparatively, 14.9% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares MediciNova and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares MediciNova and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|MediciNova Competitors||$2.04 billion||$133.73 million||-3.28|
MediciNova’s peers have higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of recent ratings and target prices for MediciNova and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
MediciNova currently has a consensus price target of $22.00, indicating a potential upside of 81.07%. As a group, “Pharmaceutical preparations” companies have a potential upside of 49.88%. Given MediciNova’s stronger consensus rating and higher possible upside, equities analysts plainly believe MediciNova is more favorable than its peers.
Risk & Volatility
MediciNova has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, MediciNova’s peers have a beta of 1.07, meaning that their average share price is 7% more volatile than the S&P 500.
MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company's product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders consisting of primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction. Its product pipeline also comprises MN-221 (bedoradrine), a selective -adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.